文献速递白血病

10天地西他滨联合维奈克拉治疗不适合强化疗初诊及复发难治急性髓系白血病的单中心2期试验

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
PubMed 文献 · Lancet Haematol · 2020-09-05

该单中心2期试验纳入168例老年或不适合强化疗的初诊AML、继发性AML及复发难治AML患者,接受10天地西他滨联合维奈克拉治疗。总缓解率74%(95%CI 67-80),初诊AML达89%。

要点

  • 10天地西他滨联合维奈克拉在初诊不适合强化疗AML中总缓解率达89%。
  • 3/4级中性粒细胞减少合并感染发生率为47%,需注意感染防治。

核心结论

  • 10天地西他滨联合维奈克拉安全性可控,在初诊AML及部分分子定义的复发难治AML中显示高活性。

研究设计与样本

  • 单中心2期试验,在MD Anderson癌症中心纳入168例>60岁初诊不适合强化疗AML、继发性AML及复发难治AML患者。
  • 治疗方案为地西他滨20 mg/m2静脉注射10天联合口服维奈克拉400 mg每日诱导,巩固期为地西他滨5天联合维奈克拉每日。
  • 主要终点为总缓解率,次要终点包括安全性、总生存和缓解持续时间。

主要发现

  • 总缓解率74%(125/168,95%CI 67-80);初诊AML 89%(62/70,95%CI 79-94),未治疗继发性AML 80%(12/15,95%CI 55-93),治疗后继发性AML 61%(17/28,95%CI 42-76),复发难治AML 62%(34/55,95%CI 49-74)。

关键数值与推荐

  • 总缓解率74%(95%CI 67-80),初诊AML 89%(95%CI 79-94),复发难治AML 62%(95%CI 49-74)。

临床怎么用

  • 对于>60岁不适合强化疗的初诊AML患者,可考虑10天地西他滨联合维奈克拉方案。
  • 治疗期间需密切监测感染,3/4级中性粒细胞减少合并感染发生率达47%。

局限性

  • 单中心2期试验,样本量有限,结果需更大规模随机研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venetoclax combined with hypomethylating agents is a new standard of care for newly diagnosed patients with acute myeloid leukaemia (AML) who are 75 years or older, or unfit for intensive chemotherapy. Pharmacodynamic studies have suggested superiority of the longer 10-day regimen of decitabine that has shown promising results in patients with high-risk AML in phase 2 trials. We hypothesised that venetoclax with 10-day decitabine could have improved activity in patients with newly diagnosed AML and those with relapsed or refractory AML, particularly in high-risk subgroups. METHODS: This single centre, phase 2 trial was done at the University of Texas MD Anderson Cancer Center (Houston, TX, USA). The study enrolled older patients (aged >60 years) with newly diagnosed AML, not eligible for intensive chemotherapy; secondary AML (progressed after myelodysplastic syndrome or chronic myelomonocytic leukaemia); and relapsed or refractory AML. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 3 or less, white blood cell count less than 10 × 109 per L, and adequate end-organ function. Patients with favourable-risk cytogenetics (eg, t[15;17] or core-binding factor AML) or who had received previous BCL2-inhibitor therapy were excluded. Patients received decitabine 20 mg/m2 intravenously for 10 days with oral venetoclax 400 mg daily for induction, followed by decitabine for 5 days with daily venetoclax for consolidation. The primary endpoint was overall response rate. The secondary endpoints analysed within this report include safety, overall survival, and duration of response, in keeping with recommendations of European LeukemiaNet 2017 guidelines. All patients who received at least one dose of treatment were eligible for safety and response assessments. The trial was registered on ClinicalTrials.gov (NCT03404193) and continues to accrue patients. FINDINGS: Between Jan 19, 2018, and Dec 16, 2019, we enrolled 168 patients; 70 (42%) had newly diagnosed AML, 15 (9%) had untreated secondary AML, 28 (17%) had treated secondary AML, and 55 (33%) had relapsed or refractory AML. The median age was 71 years (IQR 65-76) and 30% of patients had ECOG performance status of 2 or higher. The median follow-up for all patients was 16 months (95% CI 12-18; actual follow-up 6·5 months; IQR 3·4-12·4). The overall response rate was 74% (125 of 168 patients; 95% CI 67-80) and in disease subgroups were: 89% in newly diagnosed AML (62 of 70 patients; 79-94), 80% in untreated secondary AML (12 of 15 patients; 55-93), 61% in treated secondary AML (17 of 28 patients; 42-76), and 62% in relapsed or refractory AML (34 of 55 patients; 49-74). The most common treatment-emergent adverse events included infections with grades 3 or 4 neutropenia (n=79, 47%) and febrile neutropenia (n=49, 29%). 139 (83%) of 168 patients had serious adverse events, most frequently neutropenic fever (n=63, 38%), followed by pneumonia (n=17, 10%) and sepsis (n=16, 10%). The 30-day mortality for all patients was 3·6% (n=6, 95% CI 1·7-7·8). The median overall survival was 18·1 months (95% CI 10·0-not reached) in newly diagnosed AML, 7·8 months (2·9-10·7) in untreated secondary AML, 6·0 months (3·4-13·7) in treated secondary AML, and 7·8 months (5·4-13·3) relapsed or refractory AML. The median duration of response was not reached (95% CI 9·0-not reached) in newly diagnosed AML, 5·1 months (95% CI 0·9-not reached) in untreated secondary AML, not reached (95% CI 2·5-not reached) in previously treated secondary AML, and 16·8 months (95% CI 6·6-not reached) in relapsed or refractory AML. INTERPRETATION: Venetoclax with 10-day decitabine has a manageable safety profile and showed high activity in newly diagnosed AML and molecularly defined subsets of relapsed or refractory AML. Future larger and randomised studies are needed to clarify activity in high-risk subsets. FUNDING: US National Institutes of Health and National Cancer Institute.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. DiNardo CD, Maiti A, Rausch CR, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020. PMID: 32896301. doi:10.1016/S2352-3026(20)30210-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。